Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies. by King, EM et al.
Human papillomavirus DNA in men who
have sex with men: type-specific prevalence,
risk factors and implications for vaccination
strategies
E M King1, R Gilson*,1,2, S Beddows3, K Soldan4, K Panwar3, C Young1,2, P Prah1, M Jit5,6, W J Edmunds6 and
P Sonnenberg1
1Research Department of Infection and Population Health, University College London, London WC1E 6JB, UK; 2The Mortimer
Market Centre, Central and North West London NHS Foundation Trust, London WC1E 6JB, UK; 3Virus Reference Department,
Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK; 4HIV/STI Department, Centre for Communicable Disease
Surveillance and Control (CIDSC), Public Health England, 61 Colindale Avenue London, NW9 5EQ, UK; 5Modelling and Economics
Unit, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK and 6Department of Infectious Disease Epidemiology,
London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK
Background: Human papillomavirus (HPV) vaccination of girls will have relatively little effect on HPV-related disease in men
who have sex with men (MSM). We determined HPV prevalence and risk factors in MSM to inform the potential effectiveness of
vaccinating MSM.
Methods: Cross-sectional study of 522 MSM aged 18–40 attending a London sexual health clinic who completed a computer-
assisted self-interview. Urine and two swabs (anal and penile/scrotal/perianal) were collected and tested using an in-house
Luminex-based HPV genotyping system.
Results: Prevalence of DNA of the vaccine-preventable HPV types in ano-genital specimens of men was 87/511 (17.0%), 166/511
(32.5%) and 232/511 (45.4%) for the bivalent (HPV16/18), quadrivalent (HPV6/11/16/18) and nonavalent (HPV6/11/16/18/31/33/45/
52/58) vaccine types, respectively. A total of 25.1% had one of the quadrivalent types, and 7.4% had 2þ types. Median age at first
anal sex was 19 (IQR 17–23) and at first clinic attendance was 24 (IQR 20–27). The increase in the odds of any HPV infection per year
of age was 4.7% (95% CI 1.2–8.4).
Conclusions:On the basis of the current infection status, most MSM, even among a high-risk population attending a sexual health
clinic, are not currently infected with the vaccine-type HPV. A targeted vaccination strategy for MSM in the UK could have
substantial benefits.
Human papillomavirus (HPV) types 16/18 are common sexually
transmitted viruses that are classified as high-risk (HR-HPV)
because persistent infections are associated with ano-genital and
other cancers including the head and neck (Bouvard et al, 2009).
Two vaccines against HPV16/18 infection are now widely used.
The bivalent vaccine (Cervarix) protects against HPV16/18.
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The quadrivalent vaccine (Gardasil) protects against HPV16/18
and the low-risk types HPV6/11 which are responsible for the
majority of genital warts (Schiller et al, 2012). A nonavalent
vaccine targeting five additional HR-HPV types, 31/33/45/52/58
(Bouvard et al, 2009), responsible for a further 20% of cervical
cancers (Mun˜oz et al, 2003; De Sanjose et al, 2010), is expected to
be licensed (Joura et al, 2014; Olsson et al, 2014). In 2008, the UK
introduced an HPV immunisation programme for adolescent girls,
primarily as protection from cervical cancer (Jit et al, 2008;
Department of Health, United Kingdom Government, 2014). With
over 80% coverage among young girls, herd immunity is expected
to reduce HPV infection and associated disease in unvaccinated
females and heterosexual males, as has been observed in Australia
and Sweden (Leval et al, 2012; Ali et al, 2013). Provided vaccine
coverage was high, including boys in the UK programme was
considered not cost-effective, but this is being reconsidered
(Jit et al, 2008). Men who have sex with men (MSM) are unlikely
to benefit from herd immunity with the current programme (Ali
et al, 2013), are more likely to be infected with HPV (Nyitray et al,
2011) and have relatively high rates of HPV-related disease,
particularly genital warts (Anic et al, 2012) and anal cancer (Frisch
et al, 2003). Anal cancer incidence is increasing and is estimated at
1, 5 and 46/100 000 person years in all men, HIV-negative MSM
and HIV-positive MSM, respectively (Frisch et al, 2003; Wilkinson
et al, 2014).
Quadrivalent vaccine trials show efficacy against anal intrae-
pithelial neoplasia (AIN) in men. In participants with no evidence
of prior infection receiving three doses, vaccination was 78%
(95% CI 40–93) efficacious against HPV 6/11/16/18-related AIN
and 95% (95% CI 80–99) against persistent anal HPV infection
(6/11/16/18) in 16–26 year old MSM (Palefsky et al, 2011), and
90% (95% CI 69–98) efficacious against 6/11/16/18-related external
genital lesions (principally genital warts; Giuliano et al, 2011b). In
the intention-to-treat analyses, including those with prior HPV
infection, efficacy was lower, but still substantial, at 50% (95% CI
26–67) against AIN and 66% (95% CI 41–74) against genital warts.
Given the efficacy against cervical, vulval, vaginal and now anal
disease, it is expected that vaccines will protect against other
HPV16/18-related cancers for example penile and oropharyngeal.
Vaccination may also benefit previously exposed individuals
(Swedish et al, 2012; Swedish and Goldstone, 2014).
Prevalence of HPV DNA in genital specimens does not measure
cumulative exposure as 70% of genital high-risk HPV (HR-HPV)
infections in men clear by 12 months (Giuliano et al, 2011a).
Nevertheless, age-specific DNA prevalence, linked to behavioural
data, gives valuable insights into the epidemiology of HPV.
A systematic review of HPV in MSM reported a pooled anal
prevalence estimate of 64% for any HPV and 37% for any HR-
HPV in HIV-negative MSM (Machalek et al, 2012).
Given the relatively high rates of HPV-related ano-genital
disease, lack of herd immunity, and the increasing recognition of
the burden of other HPV-related disease, the question arises: is it
worthwhile to vaccinate MSM? Sexual health clinics (SHC) may
offer a convenient setting to vaccinate MSM. In the absence of
evidence of any therapeutic benefits (in clearing or preventing
disease owing to prevalent HPV infections; The FUTURE II Study
Group, 2007), the expected benefit of HPV vaccination in this
setting is maximised when the prior exposure level is low but the
future risk of acquiring vaccine-preventable infections and disease
remains high.
No studies in the UK have estimated the prevalence of the four
HPV types targeted by the quadrivalent vaccine in anal canal
samples in HIV-negative MSM (Sayers et al, 1998; Lacey et al,
1999). Five studies (from Peru (Quinn et al, 2012), Italy (Dona`
et al, 2012), Thailand (Phanuphak et al, 2013) and the Netherlands
(Van der Snoek et al, 2005; Van Aar et al, 2013) with a sample size
4100 persons have estimated the prevalence of the four HPV
types 6/11/16/18 in the anal canal of HIV-negative MSM recruited
in SHCs, with one also measuring penile HPV DNA (Van Aar et al,
2013).
The Mortimer Market Centre (MMC), in London, is one of
the largest outpatient SHCs in Europe with B80 000 patient
attendances per year (B25% are MSM). We conducted a study
to estimate the age- and type-specific prevalence of HPV
DNA, including quadrivalent (HPV6/11/16/18) and nonavalent
vaccine types (HPV6/11/16/18/31/33/45/52/58). We determined
the demographic, behavioural and health service use characteristics
associated with quadrivalent types, among MSM attending
this clinic to examine the potential benefit, barriers and opportunities
for vaccinating this group in this setting, whether with the bivalent,
quadrivalent or nonavalent vaccines.
METHODS
Recruitment and study procedures. Men attending the MMC,
who reported anal or oral sex with another man in the last five
years, aged 16–40 years inclusive, were consented to participate in
this cross-sectional study. With an estimate for HPV prevalence of
16%, a sample size of 530 men would provide 80% power to detect
a difference between two equally sized subgroups (e.g., age groups)
at the 5% significance level if the true prevalence in the subgroups
is 12% and 21%, that is, a relative risk of 1.75.
Participants completed a computer-assisted self-interview
(CASI) questionnaire covering demographics, sexual behaviour,
history of sexually transmitted infections (including HIV), knowl-
edge of HPV, attitudes to HPV vaccination and health service
use. Specimens were collected as follows: an anal specimen was
obtained by inserting a sterile plastic flocked swab that was pre-
soaked in sterile saline 3 cm into the anal canal and rotated
360 degrees; an external genital specimen was obtained by rubbing
a similar swab on the glans penis/coronal sulcus, penile shaft
including the prepuce (if present), scrotum, and perianal area; a
first-void urine specimen was collected into a 30ml universal
collection tube. Swabs were placed in UTM-RT medium (Copan
Diagnostics, Murrieta, CA, USA). Specimens were stored imme-
diately at 4 1C and transferred in cold condition to the laboratory
within 24 h.
STI diagnoses within 30 days of the study visit and HIV test
history were recorded (Health protection Agency, 2014).
Laboratory methods. In the laboratory, swab specimens were
vortexed to agitate the material from the swab into the buffer
and aliquots of 300 ml were stored at  80 1C. Urine specimens
(1ml) were centrifuged (13 000 r.p.m. for 20min) and the pellet
was resuspended in 300 ml sterile phosphate-buffered saline prior
to storage at  80 1C. Specimens were removed for batch
processing wherein all available specimens from each individual
were processed for DNA extraction and HPV testing in the same
run. Following lysis with 40 ml Qiagen Protease and 265 ml Qiagen
buffer, nucleic acid was extracted on a BioRobot Universal
platform using QIAampDNA Blood BioRobot MDx kit (Qiagen,
Crawley, West Sussex, UK). Ten microlitres of the 100 ml elution
were used for PCR amplification using the in-house single-round
multiplex PCR and type-specific infections were resolved using a
genotyping assay based on the Bio-Plex (Luminex xMAP, Bio-Rad
Laboratories, Hemel Hempstead, Hertfordshire, UK) platform
(Bissett et al, 2011). Specimen integrity was established by
incorporating a control PCR targeting the human pyruvate-
dehydrogenase gene. HPV genotypes 16/18/31/33/35/39/45/51/
52/56/58/59/68 were considered as HR-HPV types, HPV genotypes
6/11 were considered as low-risk HPV (LR-HPV) types whereas
HPV genotypes 26/53/66/70/73/82 were considered as possible
HR-HPV (Bouvard et al, 2009).
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Statistical methods. Human papillomavirus DNA prevalence was
defined as the proportion of participants with detectable HPV
DNA in X1 of the three specimen types in participants with X1
specimen type that was adequate for PCR. We estimated HPV
DNA prevalence by HPV type, HIV status, specimen type and age.
Confidence intervals (95%) were determined by the Clopper–
Pearson (exact) method. Human immunodeficiency virus status
was determined from both questionnaire data (self-reported) and
clinical records at MMC.
We used univariate logistic regression to explore the age-
relationship with HPV infection (any type, HPV16/18, any
quadrivalent vaccine types, any nonavalent vaccine types,
any HR-HPV, and HPV6/11). To explore the potential for future
HPV acquisition at any age, we examined the effect of age on
sexual behaviour using linear regression. Demographic and
behavioural risk factors for quadrivalent vaccine types were
assessed using logistic regression and we present age-adjusted
odds ratios (aOR) with 95% confidence intervals. Health service
use, HPV knowledge and STI risk perception, by quadrivalent
HPV type status, were explored to identify potential opportunities
and barriers for delivery of vaccination. Statistical analyses were
conducted using STATA v13.1 (StataCorp LP, College Station, TX,
USA).
Ethical review. The study was reviewed by the Camden and
Islington Research ethics committee (REC reference number:
09/H0722/71) and received NHS approval (R&D ref: CSP 30296).
RESULTS
Participation and response. A total of 522 MSM were recruited
between October 2010 and July 2012. The participation rate was
estimated at 81.4% from the enrolment log. All analyses were
restricted to the 511 participants (97.9%) that had X1 specimen
type that was valid for PCR. Of these, 495 completed a CASI form.
Participant characteristics. Table 1 shows demographic and
behavioural characteristics of study participants. The median age
was 30 years (IQR 25–35), with 17 participants (3.3%) younger
than 21 years. Nearly half (46.9%) were born in the UK and
another 38.4% had lived in the UK for at least 3 years. The majority
(76.2%) were of white ethnicity. Overall 91.5% self-identified as
gay/homosexual. Most participants were employed (78.8%), with
X3 years of education post-16 (68.7%). Two-thirds (65.9%)
reported higher risk drinking behaviour (identified using the
alcohol use and disorders identification test; AUDIT-C) and
one-third (29.4%) were current smokers. A total of 28.9% were
circumcised and 27 participants (5.3%) had been diagnosed as
HIV-positive and 28 (5.7%) had never had an HIV test.
The study population broadly mirrors that of MSM attending
MMC in terms of age and ethnicity, but were slightly younger
(data not shown). Men who have sex with men attending
other SHCs in England are younger and less ethnically diverse
(Public Health England, personal communication).
Human papillomavirus prevalence. The prevalence of HPV at
any site was 72.2% (95% CI 68.2–75.9) (Table 2). The prevalence of
HR-HPV types was 47.2% (95% CI 42.9–51.5). The most common
HPV types were 16, 11 and 6 with prevalence estimates of 13.5%
(95% CI 10.8–16.8), 11.5% (95% CI 9.0–14.6) and 9.4% (95% CI
7.1–12.3), respectively. At least one quadrivalent vaccine type was
detected in 32.5% of participants; 18.4% (95% CI 15.3–22.0) had a
bivalent type(s); 18.6% (95% CI 15.4–22.2) had types 6 and/or
11. The 27 HIV-positive MSM had a higher HPV prevalence
(92.6%; 95% CI 75.7–99.1) compared with the 484 HIV-negative
MSM (71.1%; 95% CI 66.8–75.1). Similarly, HIV-positive MSM
had higher prevalence of quadrivalent (59.3% (38.8–77.6) vs 31.0%
(26.9–35.3)) and nonavalent (74.1% (53.7–88.9) vs 43.8%
(39.3–48.4)) vaccine types.
Table 3 shows the prevalence of vaccine-preventable HPV types
by specimen type. A total of 132 men (29.1%) had at least one
detectable quadrivalent type in the anal canal. A further 28 men
Table 1. Demographic and behavioural characteristics of
511 participants
na Percentage
Age group (years)
18–20 17 3.3
21–25 119 23.3
26–30 127 24.9
31–35 140 27.4
36–40 108 21.1
Ethnicity
White 377 76.2
Black 30 6.1
Asian and SE asian 34 6.9
Mixed/other 51 10.3
Born in the United Kingdom
No 263 53.1
Yes 232 46.9
Sexual orientation
Gay/homosexual 452 91.5
Bisexual 42 8.5
Currently employed
No 105 21.2
Yes 390 78.8
Years of education since the age of 16 years
None 13 2.6
Up to 2 years 58 11.7
3 years or more 340 68.7
Still in education 84 17.0
Circumcised
No 349 71.1
Yes 142 28.9
Alcohol use disorders identification test—AUDIT-C
No-risk drinking 167 34.2
Risk drinking 322 65.9
Currently smokes cigarettes
No 349 70.7
Yes 145 29.4
Age at first receptive anal sex
Up to 15 years 34 7.5
16–20 years 232 51.2
21–25 years 140 30.9
26–39 years 47 10.4
Total lifetime male partners oral and anal
o20 94 19.0
21–30 73 14.8
31–100 168 34.0
101–500 159 32.2
Number of anal sex partners without a condom in the last year
(if had anal sex in last year)
No partners without a condom 173 37.4
1 124 26.8
2–4 104 22.5
5–10 40 8.6
11–30 15 3.2
430 17 1.5
Diagnosed as HIV positive
No 484 94.7
Yes 27 5.3
aTotal numbers vary for each question because of missing items.
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had quadrivalent types detected in the external genital swab so that
the prevalence in these two samples was 32.1%. Although only 16
men (3.3%) had detectable quadrivalent types in their urine, 6 of
these infections were in addition to the 160 detected in the two
swabs.
Figure 1 shows age-specific prevalence of HPV. For any HPV
type, and modelling age as a continuous variable (18–40 years),
there was a 4.7% (95% CI 1.2–8.4) increase in the odds of an HPV
infection per year. The effect was not significant when examining
age as a categorical variable, but confidence intervals are wide, and
there were few participants in the youngest category in particular
(18–20 years). There was no significant association between age
and HR-HPV, bivalent, quadrivalent or nonavalent vaccine-type
detection, considered separately. There was a 2.5% increase in the
odds of acquiring a HR-HPV infection per year between the ages of
18 and 40, although this was not statistically significant (P¼ 0.12).
The increase was 7.0% per year (95% CI  0.2–17.3) from 21 to 30
years (P¼ 0.14) and then decreased by 2.3% per year between 31
and 40 (P¼ 0.61).
Sexual behaviour. The majority of men (51.2%) reported first
receptive anal sex between 16–20 years old (Table 1). The median
Table 2. Type-specific prevalence of HPV DNA in any
specimen type (n=511)a
Percentage of
participants with
at least one
adequate sampleb
(95% CI)
Any HPV typec 72.2 (68.1–76.1)
Multiple types (2 or more) 29.2 (25.3–33.3)
Multiple HR typesd (2 or more) 17.4 (14.2–21.0)
Any quadrivalent vaccine types (6/11/16/18) 32.5 (28.6–36.7)
Any nonavalent vaccine types (6/11/16/18/
31/33/45/52/58)
45.4 (41.0–49.8)
HR-HPVd 47.2 (42.8–51.6)
16 and/or 18 18.4 (15.1–22.0)
16 13.5 (10.7–16.8)
18 6.3 (4.3–8.7)
31 1.6 (0.7–3.1)
33 2.5 (1.4–4.3)
35 3.3 (1.9–5.3)
39 5.9 (4.0–8.3)
45 9.0 (6.7–11.8)
51 4.7 (3.0–6.9)
52 7.8 (5.7–10.5)
56 5.5 (3.7–7.8)
58 2.3 (1.2–4.1)
59 1.0 (0.3–2.3)
68 7.8 (5.7–10.5)
Possibly HR-HPV 14.1 (11.3–17.4)
26 1.6 (0.7–3.1)
53 5.7 (3.8–8.0)
66 0.6 (0.1–1.7)
70 2.7 (1.5–4.6)
73 4.9 (3.2–7.1)
82 0.0 (0.0–0.7)
Low-risk HPV types
6 and/or 11 18.6 (15.3–22.2)
6 9.4 (7.0–12.3)
11 11.5 (8.9–14.6)
Abbreviations: CI¼ confidence interval; HPV¼ human papillomavirus; HR¼ high risk; HR-
HPV¼ high-risk HPV types; MSM¼men who have sex with men.
aA total of 27/511 were HIV-positive MSM in whom: 25 had detectable HPV, 16 multiple
types, 11 multiple HR types, 16 of any quadrivalent types, 20 of any nonavalent types, 20 of
HR-HPV types, 10 of HPV16/18 types and 8 of HPV6/11 types.
bHPV detected at anus (via swab) or external genitalia including penis (via swab) or urine. If
any of the 3 sample types were adequate for DNA detection then included in the
denominator.
cSample reacted to the universal probe for HPV DNA.
dHR-HPV classified according to IARC monograph carcinogenic or probably carcinogenic.
Table 3. Prevalence of vaccine-preventable HPV by specimen
type in MSM
HPV type Anal
swab
External
genital
swab
Anal or
external
genital
swab
Urine Any
specimen
type
n % n % n % n % n %
16 57 12.6 45 10.1 66 13.3 6 1.2 69 13.5
18 20 4.4 18 4.0 30 6.0 3 0.6 32 6.3
16 and 18 4 0.9 2 0.5 7a 1.4 0 0.0 7 1.4
16 or 18 69 15.2 59 13.2 82 16.5 9 1.9 87 17.0
6 39 8.6 24 5.4 48 9.6 1 0.2 48 9.4
11 36 7.9 39 8.7 58 11.7 7 1.4 59 11.5
6 and 11 5 1.1 9 2.0 12 2.4 1 0.2 12 2.4
6 or 11 65 14.3 45 10.1 82 16.5 6 1.2 83 16.2
16/18/6/11 132 29.1 107 24.0 160 32.1 16 3.3 166 32.5
31/33/45/52/
58
74 16.3 70 15.7 103 20.7 11 2.3 110 21.5
16/18/6/11/
31/33/45/52/
58
182 40.1 161 36.1 224 45.0 26 5.4 232 45.4
Number of bivalent vaccine HPV types (6/11)
0 385 84.8 385 86.3 409 82.1 477 98.2 417 81.6
1 69 15.2 59 13.2 82 16.5 9 1.9 87 17.0
2 0 0.0 2 0.5 7 1.4 0 0.0 7 1.4
Number of quadrivalent vaccine HPV types (6/11/16/18)
0 322 70.9 339 76.0 338 67.9 470 96.7 345 67.5
1 112 24.7 89 20.0 122 24.5 15 3.1 128 25.1
2 20 4.4 17 3.8 34 6.8 1 0.2 34 6.7
3 0 0.0 1 0.2 4 0.8 0 0.0 4 0.8
4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Number of nonavalent vaccine HPV types (6/11/16/18/31/33/45/
52/58)
0 272 59.9 285 63.9 274 55.0 460 94.7 279 54.6
1 144 31.7 124 27.8 152 30.5 24 4.9 157 30.7
2 30 6.6 33 7.4 58 11.7 2 0.4 59 11.6
3 7 1.5 4 0.9 12 2.4 0 0.0 14 2.7
4 1 0.2 0 0.0 1 0.2 0 0.0 1 0.2
5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
6 0 0.0 0 0.0 1 0.2 0 0.0 1 0.2
7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Total
adequate
samples
454 446 498 486 511
Abbreviations: HPV¼ human papillomavirus; MSM¼men who have sex with men.
aFor rows measuring the frequency of both HPV types (HPV16 and 18 or HPV6 and 11), when
combining specimen types, we included men in the numerator if one type was detected in
one specimen (e.g., anal) and the other type detected in another specimen (e.g., external)
so that it is possible for the total to be greater than the sum of its parts.
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age at first oral, insertive anal and receptive anal sex with a man
was 18 (IQR 16–20), 19 (IQR 17–22) and 19 (IQR 17–23),
respectively. Two-thirds of men (66.2%) had had 430 lifetime
male-sex (anal or oral) partners and only six men (1.2%) had fewer
than three lifetime partners. Of those who had an anal sex partner
in the last year, 62.6% had sex with at least one partner without a
condom. For each year increase in age, the odds of having 430
lifetime partners increased by 14.1% (95% CI 10.0–18.4) but there
was no association between age and the number of partners, new
partners or partners without a condom in the last year. For
example, the median number of male anal partners in the last year
was 6 (IQR 3–15) in men aged 18–30 and 8 (IQR 3–20) in men
aged 31–40. Younger men, aged 18–30, were more likely to have
had receptive anal sex in the last year than older men (86% vs 77%;
OR 1.8; 95% CI 1.1–2.9). The proportion of men who had sex
without a condom in the last year was higher among younger men,
(66% vs 58%; OR 1.4 95% CI 0.9–2.0) but this was not statistically
significant.
Participants had more lifetime partners than MSM who had
attended a SHC (in the last five years) in the British population in
2010–2012 measured in the Natsal-3 population-based survey.
Within Natsal-3, MSM who had attended a SHC had more lifetime
partners than those who had not. For example, 93% of MSM in our
study reported 410 lifetime partners, compared with the 78% of
MSM who had attended a SHC in Natsal-3 and with the 25%
of MSM who had not attended. (Natsal-3 team, personal
communication)
Risk factors for quadrivalent vaccine-type infection. Detection
of any quadrivalent vaccine types was associated with number of
lifetime anal or oral sex partners (aOR 2.6; 95% CI 1.4–4.8; in those
with 4100 compared with p20 partners), an HIV-positive
diagnosis (aOR 3.2; 95% CI 1.5–7.1) and rectal drug use
(aOR 2.0; 95% CI 1.1–3.6) (Supplementary Table 1). There were
no other statistically significant associations between quadrivalent
type infection and demographic, health or behavioural variables,
after adjusting for age.
Health-seeking behaviour, HPV knowledge and risk perception.
The median age at first attending a SHC in the United Kingdom
was 24 (IQR 20–27) (Table 4); 77% had visited their GP in the last
year but only 44% of these had disclosed their sexuality; 88% had
received at least one dose of hepatitis-B vaccine of whom 47% had
receivedX3 doses. Only 4% of the MSM reported that they would
probably or definitely refuse the HPV vaccine if it was offered.
There were no significant differences in health-seeking behaviour,
HPV knowledge, STI risk perception or expected vaccine
acceptance between those who had quadrivalent vaccine types
detected and those who did not.
DISCUSSION
This study, in over 500 MSM attending a London SHC, found that
two-thirds (67.5%) of men did not have any of the quadrivalent
vaccine-types detectable. A quarter (25.1%) had one type, 7.4% had
two or three types and none had all four quadrivalent types
detected. Our results are similar to those reported in a recent
systematic review of anal canal HPV prevalence in MSM
(Machalek et al, 2012). On the basis of the evidence of current
infection, there is a potential benefit in vaccinating this group of
men, which would be increased if the vaccine is also effective in
those with previous exposure (Swedish et al, 2012; Swedish and
Goldstone, 2014). These data can inform decisions on vaccination
strategies for MSM, and mathematical models of effectiveness and
cost-effectiveness.
The results suggest that extending from quadrivalent vaccine to
the nonavalent vaccine could protect a further 13–22% of
participants from HR-HPV infection. It is not clear how this
translates into potentially preventable HPV-related disease. In
men, it is estimated that quadrivalent vaccine could prevent up to
76% of anal cancers and 88% in women (Hoots et al, 2009).
A further 7% of male anal cancers might be prevented with the
nonavalent vaccine (Hoots et al, 2009).
As the MSM in our study are, on average, at higher risk, in
terms of STI acquisition, than MSM generally in the United
Kingdom, we will have underestimated the proportion of MSM
who may benefit from vaccination.
Vaccine effectiveness is highest in HPV-naive individuals
(Palefsky et al, 2011). Human papillomavirus DNA testing is a
marker of current infection and gives no information on previous
resolved episodes. The majority of HPV infections are transient,
and the median time to clearance of genital HR-HPV is estimated
to be 7.2 months (Giuliano et al, 2011a). Detecting HPV antibodies
in serum may provide evidence of previous exposure, but lacks
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Figure 1. Age-specific prevalence of HPV DNA at any site in MSM. Data available in Supplementary Table 2.
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sensitivity owing to low seroconversion rates (Carter et al, 2000;
Edelstein et al, 2011; Giuliano, 2014).
Men who have sex with men in our study reported attending a
SHC for the first time at the age of 24, an average of five years after
the initiation of anal sex. One in three MSM aged 18–23 years had
detectable quadrivalent vaccine-type DNA. We estimate that, if
33% of MSM are infected at an age of 19 years (and those negative
are all naive to the quadrivalent types), and prevalence remains at
33%, all men will have been infected by the age of 24.5 years
with an incidence of 0.9%/month, if the average duration of
infection is seven months and there is no natural immunity.
Human immunodeficiency virus-negative MSM in Thailand had a
12-month cumulative incidence of 7.2% (95% CI 3.0–17.5%) and
33.9% (21.1–54.5%) for HPV16 and HR-HPV, respectively
(Phanuphak et al, 2013). Thus it is unlikely that MSM will be
completely HPV-naive for vaccine-preventable types by the time
they first attend a SHC. That said, vaccine efficacy in MSM who are
not HPV-naive has been demonstrated. In older MSM (X26
years), including MSM with a history of HPV infection, the
quadrivalent vaccine was 55% (95% CI 8–78%) efficacious against
anal warts after five years (Swedish and Goldstone, 2014); and in
MSM (mean age 40), with a history of biopsy-confirmed and
treated high-grade AIN (HGAIN; a precursor to anal cancer), it
was 50% (95% CI 2–74%) efficacious against recurrent HGAIN
Table 4. Health service use, HPV knowledge, risk perception and vaccine acceptance in MSM with and without any detectable
quadrivalent vaccine types
Total Quadrivalent vaccine
type(s) not detected
Quadrivalent vaccine
type(s) detected
na % na % na %
Age-
adjusted
OR 95% CI P-value
Age at first attendance at UK SHC (years)
15–18 47 14.0 29 13.0 18 16.1 1 — 0.92
19–24 150 44.6 101 45.1 49 43.8 0.79 (0.39–1.59)
25–29 97 28.9 66 29.5 31 27.7 0.78 (0.34–1.81)
30–25 42 12.5 28 12.5 14 12.5 0.84 (0.30–2.34)
Visited GP in last year
No 85 17.2 60 18.0 25 15.6 1 — 0.82
Yes 381 77.1 255 76.4 126 78.8 1.18 (0.71–1.98)
Not registered with GP 28 5.7 19 5.7 9 5.6 1.13 (0.45–2.84)
Told GP sexuality
No 285 61.2 191 60.6 94 62.3 1 — 0.74
Yes 181 38.8 124 39.4 57 37.8 0.93 (0.63–1.39)
Ever had HIV test
No 28 5.7 20 6.0 8 5.0 1 — 0.70
Yes 466 94.3 314 94.0 152 95.0 1.18 (0.51–2.76)
Most recent test
In the last 12 months 360 78.6 241 78.3 119 79.3 1 — 0.77
41 year ago 98 21.4 67 21.8 31 20.7 0.93 (0.58–1.51)
Knowledge about HPV
0–4 correct answers 218 45.5 148 45.7 70 45.2 1 — 0.89
5–9 correct answers 261 54.5 176 54.3 85 54.8 1.03 (0.70–1.51)
STI risk perception-compared with other people same age
Much below average 19 3.9 14 4.2 5 3.1 1 — 0.16
Below average 66 13.4 53 15.9 13 8.2 0.68 (0.21–2.23)
Average 193 39.2 128 38.3 65 40.9 1.42 (0.49–4.12)
Above average 173 35.1 114 34.1 59 37.1 1.44 (0.49–4.18)
Much above average 42 8.5 25 7.5 17 10.7 1.89 (0.57–6.23)
STI risk perception-compared with other MSM same age
Much below average 34 7.0 26 7.9 8 5.2 1 — 0.57
Below average 119 24.5 83 25.2 36 23.2 1.40 (0.58–3.39)
Average 232 47.8 159 48.2 73 47.1 1.48 (0.64–3.43)
Above average 75 15.5 46 13.9 29 18.7 2.02 (0.81–5.08)
Much above average 25 5.2 16 4.9 9 5.8 1.84 (0.59–5.75)
Ever had hepatitis-B virus vaccine
No 63 12.8 47 14.1 16 10.1 1 — 0.23
Yes 430 87.2 287 85.9 143 89.9 1.46 (0.80–2.67)
Self-perceived likelihood of accepting the 3-dose HPV vaccine
Definitely 288 58.3 186 55.7 102 63.8 1 — 0.40
Probably 124 25.1 87 26.1 37 23.1 0.78 (0.49–1.23)
Possibly 62 12.6 47 14.1 15 9.4 0.58 (0.31–1.10)
Probably not 14 2.8 9 2.7 5 3.1 1.01 (0.33–3.10)
Definitely not 6 1.2 5 1.5 1 0.6 0.37 (0.04–3.17)
Abbreviations: CI¼ confidence interval; GP¼general practioner; HIV¼ human immunodeficiency virus; HPV¼ human papillomavirus; MSM¼men who have sex with men; SHC¼ sexual health
clinic.
aTotal numbers vary for each question because of missing items: survey questions that were not asked (because of routing) or not answered. Total including the missing items is 495.
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after 2 years (Swedish et al, 2012). Furthermore, cost-effectiveness,
taking into account indirect benefits, is not reliant on HPV-naivety
in the whole population (Kim, 2010; Zou et al, 2014).
In our MSM population, aged 18–40 years, rates of partner
change and prevalence of HPV did not decline with age and there
was no association between detectable quadrivalent vaccine types
and age at first sex. We found that the prevalence of any HPV
infection increased with age but no significant associations were
detectable when individual or grouped LR-HPV or HR-HPV were
considered. The MSM in this study reported high levels of sexual
risk behaviour. Therefore the risk of future infection with HPV is
likely to be high across all age groups as demonstrated by
comparing HPV prevalence in MSM populations with different age
distributions (Zou et al, 2014). The rapidly diminishing benefit of
vaccination with age seen in women, as a result of the age-
association with cervical HPV infection, may not apply to MSM.
Our high estimates for ano-genital HPV prevalence in HIV-
positive MSM are similar to those in larger European HIV-positive
MSM populations (Parisi et al, 2011; Videla et al, 2013). Human
immunodeficiency virus-positive MSM have more preventable
HPV infection, and HPV vaccines have been shown to be safe and
highly immunogenic in HIV-positive populations (Toft et al,
2014), so vaccination of HIV-positive MSM has great potential and
cost-effectiveness analyses should stratify by HIV status.
Although the number in each age stratum was limited, our data
suggest that HR-HPV prevalence increases until the approximate
age of 30 years. This is consistent with the results from the largest
HPV study (EXPLORE), in HIV-negative MSM in the United
States of America (n¼ 1409; median age 37; IQR 31–43), which
found no overall association with age (any type, LR-HPV or HR-
HPV) but did show an increase in HR-HPV through the age-bands
from o25 years until 30–34 years (Chin-Hong et al, 2004). After
the age of 30 years, HR-HPV prevalence may slowly decline with
age as was shown in the EXPLORE study (Chin-Hong et al, 2004)
and the HIM study (for both any HPV and HR-HPV (Nyitray et al,
2011)). We found a non-significant decrease of HR-HPV with age
between 31 and 40 years. The lack of age-association across the
entire age range in EXPLORE could be because 78% were 30 years
or older (Chin-Hong et al, 2004).
This is the first study to estimate the prevalence of all HPV
genotypes included in the bivalent, quadrivalent and nonavalent
vaccines, with sampling at multiple genital sites, in a predomi-
nantly HIV-negative population of MSM attending a SHC. It is the
first large study of HPV prevalence in MSM in the United
Kingdom, recruited from a large SHC in London. This study has
some limitations including that not all men were tested for HIV at
the clinic visit so there is a potential for undiagnosed HIV. This
potential misclassification would overestimate the HPV prevalence
in HIV-negative MSM. The sensitivity for the detection of HPV
DNA in urine is lower than genital swabs (Pathak et al, 2014) and
we observed a low HPV prevalence in this specimen type. Despite
low prevalence, we did identify HPV DNA in the urine of some
participants when it had not been detected in other specimens,
differences in HPV test sensitivity/specificity and specimen quality
across specimen types may contribute to non-concordance.
Sexual health clinics provide an opportunity to vaccinate MSM, a
group at high risk of HPV infection, who do not readily identify
themselves to GPs. Forty-five percent of MSM in a national survey
in Britain between 2010–2012 had attended a SHC in the last five
years (Sonnenberg et al, 2013). The HPV prevalence and sexual
activity levels that we report show that vaccinating MSM attending
SHCs who have the highest STI transmission risk behaviours would
undoubtedly incur a lower vaccine efficacy than vaccinating all MSM
(however that might be achieved) or all adolescent males. However,
the indirect benefits for other MSM, who are not attending SHCs,
may be substantial given the current high infection rates, and help to
compensate for the reduction in efficacy. Even if a country such as
the United Kingdom were to include all adolescent boys in a
routine vaccination programme, there would be potential benefit in
vaccinating MSM for some years as a catch-up programme.
In this study of MSM with high numbers of lifetime partners, no
participant had all four vaccine-preventable HPV types detected in
their genital specimens. Many are likely to have encountered and
resolved infections prior to the study. As vaccine effectiveness has
been demonstrated in older HPV-exposed MSM, and there appears
to be a continuing risk of acquiring new HPV infections, there is
potential benefit in vaccinating this group, at least with the
quadrivalent vaccine. The nonavalent vaccine would provide
additional protection, but the benefit in disease prevention would
need to be assessed further. The results reported here are necessary
to inform models that quantify the impact and cost-effectiveness of
HPV vaccination strategies.
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